Boehringer Ingelheim

53 marketed · 2 in Phase 3

Quick facts

Marketed products

Phase 3 pipeline

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Boehringer Ingelheim

What are Boehringer Ingelheim's marketed drugs?

Top marketed products include Jardiance, Spiriva, Ofev, Dabigatran Etexilate, Tradjenta, Tradjenta.

What is Boehringer Ingelheim's pipeline?

Boehringer Ingelheim has 2 drugs in Phase 3, 10 in Phase 2, 43 in Phase 1. Late-stage candidates include Elontril, Faldaprevir: 24-week treatment.

Related